Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 23:10:1139397.
doi: 10.3389/fmed.2023.1139397. eCollection 2023.

The mast cell exosome-fibroblast connection: A novel pro-fibrotic pathway

Affiliations

The mast cell exosome-fibroblast connection: A novel pro-fibrotic pathway

Alexandria Savage et al. Front Med (Lausanne). .

Abstract

Introduction: In addition to the traditional activation of resident receptors by release of local mediators, new evidence favors the existence of exosomes in cell-to-cell communication that mediates delivery of specific cargo to modulate recipient cell function. We report that mast cell exosomes are an additional source of pro-fibrotic substances and constitute a unique pathway for the generation of excess collagen.

Methods: We use primary human lung fibroblasts (HLFs) to demonstrate the uptake of labeled exosomes isolated from the human mast cell line HMC-1 (MC-EXOs), previously shown to contain protein cargo in common with human mast cell exosomes.

Results: The MC-EXO uptake by HLF is to the cytosol and increases both proline hydroxylation in HLF lysate and secreted collagen, within 24 h, which is sustained over 72 h, the same time required for transforming growth factor-β (TGF-β) to activate collagen synthesis in the HLFs. Unlike TGF-β, MC-EXO uptake does not induce fibrillar gene activation or invoke the Smad-nuclear transcription pathway. We show that MC-EXO uptake and TGF-β have an additive effect on collagen synthesis in HLF and postulate that MC-EXO uptake by HLFs is a contributing factor to excess collagen synthesis and represents a unique paradigm for understanding fibrosis.

Discussion: It is known that, in the lungs, mast cells are more activated and increase in number with inflammation, injury and viral infection associated with fibrosis. With the reported increased incidence of post-COVID-pulmonary fibrosis (PCPF), data from patients with severe COVID-19 are presented that show an increase in the mast cell number in lung parenchyma, the site of PCPF. Our findings provide a rationale for _targeting multiple fibrogenic pathways in the management of lung fibrosis and the use of mast cell exosomes as a biomarker for the prognostic and diagnostic management of evolving fibrotic lung disease.

Keywords: exosomes; fibroblasts; fibrosis; lung; mast cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
MC-EXO are taken up by HLFs and stimulate collagen synthesis. (A) Representative epifluorescence image of HLF uptake of MC-EXO labeled with PKH-67 (green). Nuclei are labeled with 4′,6-diamidino-2-phenylindole (DAPI) (blue). Scale bar = 15 μm. (B) Representative confocal image of HLF uptake of MC-EXO labeled with CellVue Claret Far Red (red). HLFs were transiently transfected with mNeonGreen-KDEL, a fluorescent marker of the endoplasmic reticulum. Nuclei are labeled with DAPI (blue). Note that only the HLF on the left was successfully transfected with the mNeonGreen-KDEL marker. Scale bar = 15 μm. (C) Hydroxyproline content of lysates from HLF, HLF incubated with MC-EXO (40 μg total protein) or TGF-β (10 ng/ml) at the 72 h time point. All assays performed in triplicate and normalized to total protein (μg). **P < 0.01 versus HLF, n = 5 samples/group. (D) Secreted collagen in supernatants of HLF, HLF incubated with MC-EXO (40 μg total protein) or TGF-β (10 ng/ml) for 72 h. All assays were performed in triplicate and normalized to total protein (μg). **P < 0.01 versus HLF, n = 5 samples/group.
FIGURE 2
FIGURE 2
Stimulation of collagen production by MC-EXO uptake in HLFs. (A) Secreted collagen was measured in the supernatants of HLF, HLF + MC-EXO (40 μg total protein), HLF + TGF-β (10 ng/ml), and HLF + bronchial epithelial cell exosomes (BEPI)-EXO (40 μg total protein) after 72 h. All assays performed in triplicate and normalized to total protein (μg). **P < 0.01 versus HLF, n = 5 samples/group. (B) Secreted collagen measured in the supernatants of HLF and HLF + MC-EXO (40 μg total protein) at the 48 h time point and then at the 72 h time point where the MC-EXO have been removed from the supernatant after 48 h. All assays performed in triplicate and normalized to total protein and normalized to total protein (μg). ***P < 0.001 versus HLF, n = 3 samples/group. (C) Secreted collagen measured in the supernatants of HLF and HLF with varying doses of MC-EXO. All assays performed in triplicate and normalized to total volume (700 μl). *P < 0.05, **P < 0.01. n = 3 samples/group.
FIGURE 3
FIGURE 3
Uptake of MC-EXO by HLF stimulates collagen synthesis via a Smad-independent pathway and with different kinetics from TGF-β. (A) MC-EXO (40 μg total protein, black bars) and TGF-β (10 ng/ml, dark gray bars) stimulated collagen secretion in HLFs after 24, 48, and 72 h and in untreated HLFs. Shown is the inhibition of TGF-β stimulated collagen secretion in HLFs by the TGF-βR1 inhibitor SB525334 (TGF-βR1 INH, 10 μM, light gray bars). All assays performed in triplicate and normalized to total protein (μg). ***P < 0.001 versus HLF, n = 6 samples/group. (B) Western blot of HLF lysates at 24 h and after treatment with TGF-β (10 ng/ml) or MC-EXO (40 μg total protein). Smad 2/3 and p-Smad 2/3 show signaling via the TGF-β pathway. GAPDH is loading control. Western blot was performed twice with associated quantification. (C) Collagen 1 and collagen 3 mRNA expression in HLFs and HLFs treated with either TGF-β or MC-EXO analyzed by RealTime qPCR and normalized to GAPDH mRNA. ***P < 0.001, n = 4 samples/group.
FIGURE 4
FIGURE 4
MC-EXOs and TGF-β have an additive effect on collagen synthesis in HLFs. Secreted collagen measurements in the supernatants of HLF s and HLFs incubated with MC-EXO (40 μg) or TGF-β (10 ng/ml) with and without the TGF-βR1 inhibitor SB525334 (10 μM) for 72 h. All assays were performed in triplicate and normalized to total protein (μg). *P < 0.05, **P < 0.01, n = 5 samples/group.
FIGURE 5
FIGURE 5
SARS-Cov-2 infection increases lung parenchymal mast cells. Cadaveric lungs from patients infected with SARS-CoV-2 (n = 10) or biopsies from donor lungs tissue prior to transplant (n = 4) were stained with the mast cell marker avidin HRP. Mast cells were quantified in parenchyma and airway walls (medium sized airways, 0.5–5.0 mm) **P < 0.01 SARS-Cov-2 parenchyma versus normal parenchyma.
FIGURE 6
FIGURE 6
Cartoon depicting two parallel pathways in mast cells leading to fibroblast activation and excess collagen production. One pathway depicts classic mast cell degranulation with release of pro-fibrotic mediators like histamine and renin (ANG II), acting on the resident receptors on fibroblasts that activate the collagen synthesis pathway. The other pathway is the newly identified exosome pathway where shed exosomes are taken up in the cytosol of fibroblasts leading to proline hydroxylation and increased collagen production.

Similar articles

Cited by

References

    1. Noble P, Barkauskas C, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest. (2012) 122:2756–62. 10.1172/JCI60323 - DOI - PMC - PubMed
    1. Bonniaud P, Margetts P, Ask K, Flanders K, Gauldie J, Kolb M. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol. (2005) 175:5390–5. 10.4049/jimmunol.175.8.5390 - DOI - PubMed
    1. Martinez F, Collard H, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. (2017) 3:17074. 10.1038/nrdp.2017.74 - DOI - PubMed
    1. Noble P, Albera C, Bradford W, Costabel U, du Bois R, Fagan E, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. (2016) 47:243–53. 10.1183/13993003.00026-2015 - DOI - PMC - PubMed
    1. Vancheri C, Kreuter M, Richeldi L, Ryerson C, Valeyre D, Grutters J, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: results of the INJOURNEY trial. Am J Respir Crit Care Med. (2017) 197:356–63. 10.1164/rccm.201706-1301OC - DOI - PubMed

Grants and funding

This study was funded by the Anna-Maria and Stephen Kellen Foundation and the Morgan Family Foundation.

LinkOut - more resources

  NODES
Note 1
twitter 2